AHL 2011: A Lysa randomized phase III study of a treatment driven by early PET response compared to a standard treatment in patients with Ann Arbor stage III-IV or high-risk IIB Hodgkin lymphoma.

被引：0

作者：

Casasnovas, Rene-Olivier

Meignan, Michel

Reman, Oumedaly

Gaillard, Isabelle

Stamatoullas, Aspasia

Brice, Pauline

Salles, Gilles A.

Bouabdallah, Reda

Bologna, Serge

Nicolas-Virelizier, Emmanuelle

Morschhauser, Franck

Janvier, Maud

Andre, Marc

Berriolo-Riedinger, Alina

Traverse-Glehen, Alexandra

Edeline, Veronique

Dartigues, Peggy

Parrens, Marie

Mounier, Nicolas

Ferme, Christophe

机构：

[1] Hop Le Bocage, Dijon, France

[2] Hop Henri Mondor, F-94010 Creteil, France

[3] CHU Caen, F-14000 Caen, France

[4] Ctr Henri Becquerel, F-76038 Rouen, France

[5] Hosp St Louis, Paris, France

[6] Ctr Hosp Lyon Sud, Oullins, France

[7] Inst J Paoli I Calmettes, F-13009 Marseille, France

[8] Ctr Hosp Univ, Nancy, France

[9] Ctr Leon Berard, F-69373 Lyon, France

[10] Hop Claude Huriez, Lille, France

[11] Inst Curie, Paris, France

[12] Ctr Hosp Univ Mt Godinne, Dinant, Belgium

[13] Ctr Georges Francois Leclerc, Dijon, France

[14] Hop Lyon Sud, Hosp Civils Lyon, Pierre Benite, France

[15] Inst Gustave Roussy, Villejuif, France

[16] Ctr Hosp Univ, Bordeaux, France

[17] Ctr Hosp Univ Archet, Nice, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS8615

引用

页数：1

共 50 条

[1] Randomized Phase III Study Comparing an Early PET Driven Treatment De Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study
Casasnovas, Olivier
Brice, Pauline
Bouabdallah, Reda
Salles, Gilles A.
Stamatoullas, Aspasia
Dupuis, Jehan
Reman, Oumedaly
Gastinne, Thomas
Joly, Bertrand
Bouabdallah, Krimo
Nicolas-Virelizier, Emmanuelle
Bologna, Serge
Morschhauser, Franck
Delarue, Richard
Farhat, Hassan
Quittet, Philippe
Berriolo-Riedinger, Alina
Tempescul, Adrian
Edeline, Veronique
Maisonneuve, Herve
Eisenmann, Jean Claude
Traverse-Glehen, Alexandra
Andre, Marc
Mounier, Nicolas
Meignan, Michel
Ferme, Christophe
BLOOD, 2015, 126 (23)
[2] Randomized phase III study comparing an early PET driven treatment deescalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study.
Casasnovas, Olivier
Brice, Pauline
Bouabdallah, Reda
Salles, Gilles A.
Stamatoulas, Aspasia
Dupuis, Jehan
Reman, Oumedaly
Gastinne, Thomas
Joly, Bertrand
Bouabdallah, Kamal
Nicolas-Virelizier, Emmanuelle
Feugier, Pierre
Morschhauser, Franck
Delarue, Richard
Berriolo-Riedinger, Alina
Edeline, Veronique
Traverse-Glehen, Alexandra
Andre, Marc
Mounier, Nicolas
Meignan, Michel
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Randomized Phase III Study Comparing an Early PET-Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients With Advanced-Stages Hodgkin Lymphoma: Final Analysis of the AHL2011 LYSA Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 9 - 11
[4] Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients
Bruzzone, M
Miglietta, L
Franzone, P
Gadducci, A
Boccardo, F
GYNECOLOGIC ONCOLOGY, 2004, 93 (02) : 345 - 352
[5] Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: A retrospective study
Sovak, Mika A.
Hensley, Martee L.
Dupont, Jakob
Ishill, Nicole
Alektiar, Kaled M.
Abu-Rustum, Nadeem
Barakat, Richard
Chi, Dennis S.
Sabbatini, Paul
Spriggs, David R.
Aghajanian, Carol
GYNECOLOGIC ONCOLOGY, 2006, 103 (02) : 451 - 457
[6] ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.
Carde, Patrice P.
Karrasch, Matthias
Fortpied, Catherine
Brice, Pauline
Khaled, Hussein Mustafa
Caillot, Denis
Gaillard, Isabelle
Bologna, Serge
Ferme, Christophe
Lugtenburg, Pieternella
Morschhauser, Franck
Aurer, Igor
Coiffier, Bertrand
Cantin, Guy
Seftel, Matthew D.
Wolf, Max
Glimelius, Bengt
Sureda, Anna
Mounier, Nicolas
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[7] Upfront autologous hematopoietic stem cell transplantation in patients with high-risk stage III to IV Hodgkin lymphoma: a multicenter retrospective cohort study
Gao, Li
Xiang, Xixi
Zhang, Cheng
Gao, Lei
Yang, Tonghua
Wang, Sanbin
Li, Bin
Lou, Shifeng
Su, Yi
Liu, Yao
Zhang, Xi
HEMATOLOGY, 2019, 24 (01) : 225 - 231
[8] A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial
Crump, Michael
Leppae, Sirpa
Fayad, Luis E.
Lee, Je-Jung
Di Rocco, Alice
Ogura, Michinori
Hagberg, Hans
Schnell, Frederick
Rifkin, Robert M.
Mackensen, Andreas
Offner, Fritz
Pinter-Brown, Lauren
Smith, Sonali M.
Tobinai, Kensei
Yeh, Su-Peng
Zhu, Jun
Hahka-Kemppinen, Marjo
Thornton, Donald
Shi, Peipei
Lin, Boris
Kahl, Brad S.
Schmitz, Norbert
Savage, Kerry J.
Habermann, Thomas M.
BLOOD, 2013, 122 (21)
[9] Patterns of PET positive residual tissue at early interim staging and risk of treatment failure in advanced-stage Hodgkin's Lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group
Ferdinandus, J.
van Heek, L.
Roth, K. S.
Dietlein, M.
Eich, H.
Baues, C.
Borchmann, P.
Kobe, C.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S47 - S47
[10] Fludarabine compared with CVP chemotherapy in newly diagnosed patients with stages III and IV low grade malignant non-Hodgkin's lymphoma. Final analysis of a prospective randomized phase III intergroup study in 381 patients.
Hagenbeek, A
Eghbali, H
Monfardini, S
Resegotti, E
Hoskin, J
de Wolf-Peeters, C
McLennan, K
Staab-Renner, E
Schott, A
Teodorovic, I
Negrouk, A
van Glabbeke, M
Marcus, R
BLOOD, 2001, 98 (11) : 843A - 843A

← 1 2 3 4 5 →